Aim 2b: Pioneering Advances in Care & Education (PACE)

Inclusion Criteria

• Newly diagnosed prostate cancer (PCa) (within 3-months).
• Documentation of a low-risk PCa diagnosis as evidenced by clinical features of the following criteria: * PSA test at diagnosis =< 15 ng/ml * Localized PCa (cT1/T2,N0,M0) * Biopsy Gleason grade 2-6 OR (or 3+4 AND <=33% cores are positive for adenocarcinoma) ** A minimum of 10 diagnostic cores taken by a systematic directed approach. Sampling may be obtained by target transrectal ultrasound (TRUS) or magnetic resonance imaging (MRI) imaging. * No treatment yet ** No previous radiation or simultaneous use of androgen deprivation ** Prior use of 5-alpha reductase inhibitor is allowed if they have been stopped for 6 or more months and biopsy performed when patient was not taking the drug * English language proficient and ability to provide informed consent form (ICF) * Managing urologist considers them a candidate for active surveillance
• Written informed consent (and assent when applicable) obtained from subject and ability for subject to comply with the requirements of the study, including the ability to read and speak English.

Exclusion Criteria

• Have pursued any active therapy for prostate cancer will be excluded.
• Are unable to read/speak English.
• If their managing urologist does NOT deem them as a candidate for active surveillance.